Literature DB >> 29186373

CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease.

Simone L Verweij1, Raphaël Duivenvoorden1,2, Lotte C A Stiekema1, Nick S Nurmohamed1, Fleur M van der Valk1, Miranda Versloot3, Hein J Verberne4, Erik S G Stroes1, Matthias Nahrendorf5, Siroon Bekkering1,3, Sophie J Bernelot Moens1.   

Abstract

AIMS: Circulating monocytes infiltrate the plaque and differentiate into macrophages, contributing to an inflammatory environment which is associated with higher risk of cardiovascular events. Although the pivotal role of circulating monocytes in plaque inflammation has been firmly established, the search continues to identify specific monocyte subsets that may be especially atherogenic. Therefore, we evaluated the relation between monocyte phenotype, particularly surface receptor expression, and arterial wall inflammation in patients at increased cardiovascular risk. METHODS AND
RESULTS: We performed a multivariate linear regression analysis in 79 patients at increased cardiovascular risk who had both an 18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess arterial wall inflammation and extensive monocyte characterization (using flow cytometry). We found that CCR2, a monocyte chemokine receptor essential for transmigration, significantly correlates with arterial wall inflammation. This relationship was independent of traditional cardiovascular risk factors and statin use (β = 0.429, P = 0.015). We found no relation between arterial wall inflammation and monocyte count or monocyte subsets, namely CD14+CD16-, CD14+CD16+, CD14+CD16 ++, CCR5+, CD18+, CD11b+, or CD11c+ monocytes.
CONCLUSION: Monocyte CCR2 expression is associated with arterial wall inflammation in patients at increased cardiovascular risk. Our data warrant further studies to assess if inhibition of CCR2 may attenuate atherosclerotic plaque inflammation. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29186373     DOI: 10.1093/cvr/cvx224

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  17 in total

Review 1.  Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis.

Authors:  Ira Tabas; Karin E Bornfeldt
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

3.  Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

Authors:  Lotte C A Stiekema; Erik S G Stroes; Simone L Verweij; Helina Kassahun; Lisa Chen; Scott M Wasserman; Marc S Sabatine; Venkatesh Mani; Zahi A Fayad
Journal:  Eur Heart J       Date:  2019-09-01       Impact factor: 29.983

4.  Role of CCR2 in the Development of Streptozotocin-Treated Diabetic Cardiomyopathy.

Authors:  Xin Tan; Lizhi Hu; Zhiping Shu; Long Chen; Xiangrao Li; Meng Du; Dan Sun; Xiaoxiang Mao; Shan Deng; Kai Huang; Fengxiao Zhang
Journal:  Diabetes       Date:  2019-08-22       Impact factor: 9.461

Review 5.  Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease.

Authors:  Karina Gasbarrino; Diana Di Iorio; Stella S Daskalopoulou
Journal:  Eur Heart J       Date:  2022-02-10       Impact factor: 29.983

6.  Myeloid CCR2 Promotes Atherosclerosis after AKI.

Authors:  Anne M Hüsing; Vera C Wulfmeyer; Svenja Gaedcke; Susanne V Fleig; Song Rong; David DeLuca; Hermann Haller; Roland Schmitt; Sibylle von Vietinghoff
Journal:  J Am Soc Nephrol       Date:  2022-05-10       Impact factor: 14.978

Review 7.  Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.

Authors:  Daniel Clark Files; Frank Tacke; Alexandra O'Sullivan; Patrick Dorr; William G Ferguson; William G Powderly
Journal:  PLoS Pathog       Date:  2022-06-24       Impact factor: 7.464

8.  LDL associates with pro-inflammatory monocyte subset differentiation and increases in chemokine receptor profile expression in African Americans.

Authors:  Cristhian A Gutierrez-Huerta; Briana S Turner; Sophie E Claudel; Nicole Farmer; Rafique Islam; Valerie M Mitchell; Billy S Collins; Yvonne Baumer; Alan T Remaley; Tiffany M Powell-Wiley
Journal:  Int J Cardiol       Date:  2022-04-15       Impact factor: 4.039

Review 9.  Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response.

Authors:  Namrita Kaur; Yingshu Guan; Rida Raja; Andrea Ruiz-Velasco; Wei Liu
Journal:  Front Physiol       Date:  2021-06-21       Impact factor: 4.566

10.  Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT.

Authors:  Simone L Verweij; Lotte C A Stiekema; Ronak Delewi; Kang H Zheng; Sophie J Bernelot Moens; Jeffrey Kroon; Charlotte I Stroes; Miranda Versloot; Jan J Piek; Hein J Verberne; Erik S G Stroes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.